
Commentary|Videos|December 13, 2024
Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer
Author(s)Mariya Rozenblit, MD
Fact checked by: Ashling Wahner , Chris Ryan
Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.
Advertisement
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine, discusses findings from a study evaluating the prevalence of actionable genomic alterations and the predictive value of tumor mutational burden (TMB) for the efficacy of immune checkpoint inhibitors in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































